- Home
- ANGH vs CODX Comparison
ANGH vs CODX Comparison
Compare ANGH & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- CODX
- Stock Information
- Founded
- ANGH 2012
- CODX 2013
- Country
- ANGH United Arab Emirates
- CODX United States
- Employees
- ANGH N/A
- CODX N/A
- Industry
- ANGH Telecommunications Equipment
- CODX Medical/Dental Instruments
- Sector
- ANGH Consumer Discretionary
- CODX Health Care
- Exchange
- ANGH Nasdaq
- CODX Nasdaq
- Market Cap
- ANGH 18.7M
- CODX 15.6M
- IPO Year
- ANGH N/A
- CODX 2017
- Fundamental
- Price
- ANGH $2.82
- CODX $0.36
- Analyst Decision
- ANGH
- CODX Buy
- Analyst Count
- ANGH 0
- CODX 2
- Target Price
- ANGH N/A
- CODX $2.00
- AVG Volume (30 Days)
- ANGH 5.1K
- CODX 62.4M
- Earning Date
- ANGH 12-19-2025
- CODX 11-13-2025
- Dividend Yield
- ANGH N/A
- CODX N/A
- EPS Growth
- ANGH N/A
- CODX N/A
- EPS
- ANGH N/A
- CODX N/A
- Revenue
- ANGH $78,093,405.00
- CODX $507,892.00
- Revenue This Year
- ANGH N/A
- CODX N/A
- Revenue Next Year
- ANGH N/A
- CODX $31.58
- P/E Ratio
- ANGH N/A
- CODX N/A
- Revenue Growth
- ANGH 88.72
- CODX N/A
- 52 Week Low
- ANGH $2.53
- CODX $0.23
- 52 Week High
- ANGH $9.40
- CODX $1.55
- Technical
- Relative Strength Index (RSI)
- ANGH 46.49
- CODX 47.16
- Support Level
- ANGH $2.80
- CODX $0.38
- Resistance Level
- ANGH $2.84
- CODX $0.40
- Average True Range (ATR)
- ANGH 0.05
- CODX 0.05
- MACD
- ANGH 0.01
- CODX -0.01
- Stochastic Oscillator
- ANGH 49.79
- CODX 24.64
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.